M yofilament contraction is initiated by interaction between the thin actin and thick myosin filaments. This actin-myosin interaction (ie, thin-filament myosin cross-bridge binding) and the magnitude of myofilament force generation are tightly regulated by muscle length, Ca 2+ binding, and protein phosphorylation. 1 Defective proteins resulting
from mutations in genes encoding sarcomeric proteins may directly impair regulation of muscle contraction and manifest themselves as phenotypic aberrations of the heart. Hypertrophic cardiomyopathy (HCM) reflects the pathological phenotype associated with sarcomeric gene mutations. 2, 3 Affecting 1:500 individuals worldwide, HCM is the most common cause of sudden death in young people. 2 Genotyping studies have identified a disease-causing mutation in ≈70% of all patients with HCM. 4 Mutations in thick-filament-encoding genes, MYH7 (β-myosin heavy chain [β-MyHC]) and MYBPC3 (cardiac myosin-binding protein-C [cMyBP-C]), account for ≈80% of all identified sarcomere mutations, whereas ≈18% of the mutations are found in thin-filament-encoding genes, TNNI3 (cardiac troponin I [cTnI]), TNNT2 (cardiac troponin T [cTnT]), TNNC1 (cardiac troponin C), TPM1 (α-tropomyosin), and ACTC1 (α-cardiac actin). 5 The remaining 2% are attributed to incidental mutations in the thick-filament genes, MYL3 and MYL2, encoding the regulatory and essential myosin light chain, and the sarcomere-associated gene TTN, which encodes titin. 5 On the basis of the numerous sarcomeric gene mutations, HCM is referred to as a disease of the sarcomere.
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Both animal 6, 7 and clinical [8] [9] [10] studies have shown that carriers of HCM-causing mutations demonstrate early signs of cardiac dysfunction, even before a hypertrophic phenotype is observed. Additionally, sudden cardiac death occurs in young individuals in the absence of clinically detectable cardiac hypertrophy. 11 This suggests that the initial defects in cardiac performance are triggered by mutant sarcomeric proteins rather than remodeling of the heart. Sarcomere mutations may directly impair myofilament function and contractile performance of the heart 3 or indirectly via changes in intracellular Ca 2+ handling. 12 Because the myofilaments represent a major intracellular buffer of Ca 2+ , any perturbation in myofilament Ca 2+ sensitivity may provide a substrate for cardiac arrhythmias. Only recently, Knollmann's group 13 showed that TNNT2 mutations alter intracellular Ca 2+ handling via myofilament Ca 2+ sensitization in transgenic mice models, which was associated with altered action potential regulation and occurrence of arrhythmias. This implies that myofilament Ca 2+ sensitivity is central in HCM pathology.
Whether or not myofilament sensitization to Ca 2+ is of relevance in human HCM is a matter of ongoing research. [14] [15] [16] Our recent studies in manifest HCM with MYBPC3 mutations showed higher myofilament Ca 2+ sensitivity compared with nonfailing donor myocardium. 15, 16 However, high Ca 2+ sensitivity coincided with low phosphorylation of target proteins of the β-adrenergic signaling pathway, cTnI, and cMyBP-C and was normalized to donor values by exogenous protein kinase A (PKA) treatment. 15 This suggests that the high myofilament Ca 2+ sensitivity observed in human HCM with MYBPC3 mutations is attributable to secondary disease-related posttranslational modifications rather than the mutation itself. In addition to posttranslational protein modifications, muscle length represents an important determinant of myofilament Ca 2+ sensitivity. Recently, we observed impairment of length-dependent sarcomere activation evident from a blunted length-dependent increase in myofilament Ca 2+ sensitivity in HCM with MYBPC3 mutations. 15 Under normal conditions, intracellular Ca 2+ buffering will increase with increased myofilament Ca 2+ sensitivity on myofilament lengthening. 17, 18 Perturbations in length-dependent myofilament activation will alter Ca 2+ buffering by the sarcomeres and may provide a basis for altered Ca 2+ handling in HCM.
In the present study, we investigated whether perturbed length-dependent activation rather than high myofilament Ca 2+ sensitivity is a common pathomechanism in human HCM with mutations in thick-and thin-filament genes. Measurements in sarcomere mutation-positive HCM were compared with sarcomere mutation-negative HCM (HCM smn ) and nonfailing donors. Our study shows that mutation-related changes in myofilament Ca 2+ sensitivity are diverse and depend on the affected gene. We observed impaired length-dependent sarcomere activation in all HCM samples. The blunted length dependence of sarcomeres was attributable to low phosphorylation of PKA targets compared with donor myocardium in patients with MYBPC3 truncating mutations and HCM smn but a direct consequence of HCM missense mutations. Using troponin exchange in HCM cardiomyocytes with a homozygous TNNT2 and a heterozygous TNNI3 mutation, we provide evidence that <50% of poison peptide is sufficient to impair length-dependent activation of the sarcomeres. Because most patients carry a heterozygous sarcomere mutation that may result in relatively low levels of mutant (poison) peptide, impaired length-dependent sarcomere activation represents a pathomechanism in HCM.
Methods
An expanded version of the Methods section can be found in the online-only Data Supplement.
Myocardial Samples
Left ventricular septum tissue was obtained from patients with HCM harboring thick-and thin-filament gene mutations during myectomy surgery to relieve left ventricular outflow obstruction. Hypertrophic obstructive cardiomyopathy was evident from the high septal thickness (normal value <13 mm) and high left ventricular outflow tract pressure gradient (normal value <30 mm Hg). Clinical characteristics and mutation information of patients with HCM are listed in Table 1 by LIZA GORSTAN on September 4, 2013 http://circres.ahajournals.org/ Downloaded from was also obtained from 1 end-stage failing patient with HCM carrying a homozygous TNNT2 mutation (TNNT2 mut ). Septum myectomy tissue from 7 patients with HCM in whom no mutation was found after screening of 8 genes (HCM smn ) and cardiac tissue from 12 nonfailing donors served as controls. Donors (age range, 14-65 years; mean, 39±5 years; 9/3 male/female, respectively) had no history of cardiac abnormalities, normal ECG, and normal ventricular function on echocardiography within 24 hours of heart transplantation. Samples were obtained after written informed consent, and the study protocol was approved by the local ethics committees.
Isometric Force Measurements and Protein Analysis
Analysis of single cardiomyocyte force measurements and sarcomeric protein phosphorylation was performed as described previously. 15, 19, 20 
Exchange of Recombinant Human Troponin Complex
Expression, purification, and reconstitution of recombinant human wild-type cardiac troponin in single cardiomyocytes from the TNNT2 mut heart and 1 of the TNNI3 mut hearts were performed as described previously. 21 Evaluation of the degree of exchange into cardiomyocytes was determined by labeling cTnT of wild-type recombinant cardiac troponin with a myc-tag to allow differentiation between endogenous and recombinant wild-type cTnT in Western blot analysis.
Data Analysis
Data are presented as mean±SEM of all single cardiomyocytes per patient/donor group. To take into account the repeated sample assessments within patient/donor groups, multilevel analysis was performed. Comparison between all groups was performed for Ca 2+ sensitivity at 2.2-μm sarcomere length and length-dependent activation of cardiomyocytes before and after PKA. Paired-group comparisons were performed for maximal developed force (F max ) at 1.8-and 2.2-μm sarcomere length before and after PKA.
Detailed explanation of the data analyses, significance levels (exact P values), and 95% confidence intervals for all comparisons are given in the online-only Data Supplement.
Results

Myofilament Ca 2+ Sensitivity in HCM Compared With Nonfailing Donors
To assess myofilament Ca 2+ sensitivity, force-Ca 2+ relations were constructed for all cardiac samples at a sarcomere length of 2.2 μm. Ca 2+ sensitivity for all HCM samples was significantly higher compared with donors on the basis of their lower EC 50 values ( Figure 1A ). Because the high Ca 2+ sensitivity may be attributable to low phosphorylation levels of PKAtarget proteins, measurements were repeated after PKA treatment. The PKA-induced reduction in Ca 2+ sensitivity (ΔEC 50 ) was larger in all HCM groups compared with donors (with significant changes in MYBPC3 mut , MYH7 mut , and TNNI3 mut ), except for TNNT2 mut , which only showed a minor nonsignificant change ( Figure 1B ). After PKA treatment, myofilament Ca 2+ sensitivity was close to donor values in MYBPC3 mut , TPM1 mut , and HCM smn , whereas Ca 2+ sensitivity remained significantly higher compared with donor values in MYH7 mut and TNNT2 mut ( Figure 1C ). Interestingly, after PKA treatment, Ca 2+ sensitivity was significantly lower in TNNI3 mut compared with HCM smn and donor values.
F max at a sarcomere length of 2.2 μm was significantly lower in all HCM groups compared with donors and was not corrected by PKA treatment (Online Table I ). In addition, the steepness of the force-Ca 2+ relation was significantly lower and not corrected by PKA in all HCM groups compared with donors (data not shown).
Length-Dependent Myofilament Force Characteristics
Force development was measured at various [Ca 2+ ] and 2 sarcomere lengths to determine length-dependent activation of myofilaments (Figure 2A) . After a sarcomere length increase from 1.8 to 2.2 μm at maximal Ca 2+ activation, donor samples showed a significant increase in F max (Table 2) , which is in accordance with the well-known effects of length on force development. 22 A significant length-dependent increase in F max was observed in MYBPC3 mut , MYH7 mut , TPM1 mut , and HCM smn heart samples, whereas no significant increase in F max was found for both TNNT2 mut and TNNI3 mut . As illustrated in Table 2 , the ΔF max (difference in F max between sarcomere lengths of 1.8 and 2.2 μm) was much lower in HCM with missense mutations compared with the other groups.
To investigate the length-dependent increase in myofilament Ca 2+ sensitivity, force at submaximal [Ca 2+ ] was normalized to the F max to obtain normalized force-Ca 2+ relations at both sarcomere lengths ( Figure 2B ). For all HCM and donor groups, the normalized force-Ca 2+ relation shifted to the left as sarcomere length increased, indicative of increased Ca 2+ sensitivity. However, the increase in myofilament Ca 2+ sensitivity on an increase in sarcomere length (ΔEC 50 ) was significantly lower in all sarcomere mutation-positive HCM and HCM smn samples compared with donors ( Figure 2C ).
Stimulation of the β-adrenergic receptor pathway has been shown to enhance the length-dependent shift in the force-Ca 2+ relation, suggesting a modulating role for PKA-mediated protein phosphorylation in length-dependent sarcomere activation. 23, 24 Because previous studies showed lower phosphorylation levels of myofilament PKA target proteins in HCM compared with donors, 15, 16 the blunted length-dependent activation in HCM compared with donors may be explained by a difference in protein phosphorylation level. Indeed, analysis of protein phosphorylation showed lower phosphorylation levels of both cTnI and cMyBP-C in all HCM groups compared with nonfailing donors, except in TNNT2 mut , in which phosphorylation of the PKA target proteins did not differ from donor ( Figure 3A) .
To test whether the blunted length-dependent change in F max and myofilament Ca 2+ sensitivity was corrected by PKAmediated phosphorylation of cMyBP-C and cTnI, force measurements were performed after pretreatment with exogenous PKA in a subset of HCM and donor samples. PKA pretreated MYBPC3 mut , MYH7 mut , and HCM smn and donor cells showed a significant increase in maximal force after a sarcomere length increase, similar to that observed in nontreated cardiomyocytes ( Table 2 ). PKA did not restore the blunted length-dependent increase in F max evident from the significantly lower ΔF max in HCM with missense mutations compared with donor ( Table 2) . Pretreatment with exogenous PKA significantly enhanced the length-dependent shift in myofilament Ca 2+ sensitivity in HCM with truncating MYBPC3 mut and HCM smn samples to values observed in donors but did not correct the blunted by LIZA GORSTAN on September 4, 2013 http://circres.ahajournals.org/ Downloaded from length-dependent change in EC 50 in all other HCM mutant groups harboring missense mutations ( Figure 2D ).
Because the MYBPC3 mut and MYH7 mut groups consisted of different mutations, we averaged functional data for each HCM mutation separately. Data are shown in Table II in the online-only Data Supplement).
PKA-Mediated Protein Phosphorylation
To determine whether the absence of an effect of PKA on sarcomere functional properties is attributable to a defect in PKA-mediated protein phosphorylation in HCM myocardium, phosphorylation status of PKA target proteins was analyzed in HCM and donor samples incubated with exogenous PKA. Figure 3B shows HCM samples incubated without and with PKA separated by 1-dimensional gel electrophoresis and stained with ProQ-Diamond and SYPRO Ruby. PKA increased phosphorylation of both PKA targets, cMyBP-C and cTnI, in HCM samples. Phosphorylation levels (normalized to untreated donor samples, which were included on the gel and set to 1; dotted line) are depicted in Figure 3C and show that phosphorylation of cMyBP-C after PKA was close to values observed in donor samples in all HCM samples. Analysis of phosphorylation at specific PKA sites (Ser275 and Ser284) on cMyBP-C confirmed increased PKA-mediated phosphorylation in HCM samples ( Figure 4 ). In addition to cMyBP-C, phosphorylation of cTnI increased by PKA in all HCM samples ( Figure 3B) , although values did not reach the level found in donor myocardium ( Figure 3C ). PKA treatment of donor samples increased cTnI phosphorylation by ≈25%. Similar data were obtained when cTnI phosphorylation was analyzed by Phos-Tag gel electrophoresis creating a pattern of unphosphorylated, monophosphorylated, and bisphosphorylated cTnI (Online Figure II) . PKA-treated HCM samples showed increased bisphosphorylated cTnI levels, but some monophosphorylated cTnI remained. Previous Phos-Tag analysis of the donor samples (n=12) revealed a distribution pattern of 7% unphosphorylated, 27% monophosphorylated, and 66% bisphosphorylated cTnI. 15 On treatment of donor samples (n=2) with PKA, cTnI was mostly bisphosphorylated (Online Figure II) .
Correction of Length-Dependent Activation in HCM With Mutant cTnT and Mutant cTnI by Human Recombinant Wild-type Troponin
To determine whether mutant sarcomeric protein is the direct cause of the blunted length-dependent increase in myofilament Ca 2+ sensitivity, we performed troponin exchange experiments in cardiomyocytes from the TNNT2 mut sample. The homozygous TNNT2 mut necessarily results in 100% mutant cTnT and thus represents a unique tool to assess the level at which mutant protein perturbs sarcomere function. Exchange with increasing concentrations of wild-type human troponin complex (0.25, 0.5, and 1 mg/mL in the exchange solution) resulted in 62±2%, 78±1%, and 86±1% troponin exchange on the basis of Western blot analyses of endogenous and myc-tag-labeled wild-type cTnT ( Figure 5A ; left blot). In exchanged cells without PKA pretreatment, replacement of mutant troponin with unphosphorylated recombinant wild-type troponin did not restore the reduced length-dependent activation to donor Figure 1 . Myofilament Ca 2+ sensitivity at a sarcomere length of 2.2 μm. A, Myofilament Ca 2+ sensitivity (EC 50 ) was significantly higher in all hypertrophic cardiomyopathy (HCM) groups compared with donors. B, The protein kinase A (PKA)induced reduction (∆EC 50 ) in myofilament Ca 2+ sensitivity was larger in HCM groups compared with donors, except in the TNNT2 mut sample, in which PKA had no significant effect. C, Myofilament Ca 2+ sensitivity was similar in MYBPC3 mut , TPM1 mut , sarcomere mutation-negative HCM (HCM smn ), and donor after treatment with PKA, whereas it was higher than donor in MYH7 mut and TNNT2 mut . PKA-treated TNNI3 mut cells showed a lower myofilament Ca 2+ sensitivity compared with HCM smn and donor. Open bar represents MYBPC3 truncating mutation; solid gray bars represent missense mutations. *P<0.05 vs donor; §P<0.05 vs TNNT2 mut ; #P<0.05 vs HCM smn . values ( Figure 5B ). However, replacement of endogenous mutant troponin by unphosphorylated recombinant troponin reduces cTnI phosphorylation in the TNNT2 mut cells. Therefore, measurements were also performed in the troponin-exchanged cells after PKA treatment to increase cTnI phosphorylation to donor levels. In cells in which 62% of mutant troponin was replaced by wild-type troponin, the length-dependent increase in myofilament Ca 2+ sensitivity was still significantly lower compared with donor values, indicating that 38% of mutant protein is sufficient to impair length-dependent activation. However, the blunted length-dependent activation was restored to donor values in TNNT2 mut -exchanged cells, harboring 22% and 14% endogenous mutant cTnT ( Figure 5C ). Similarly, exchange of mutant cTnI in 1 of the HCM samples harboring the R145W missense mutation in TNNI3 by ≈90% unphosphorylated wild-type troponin complex ( Figure 5A ; right blot) corrected length-dependent activation only after PKA treatment ( Figure 5D and 5E ). Hence, normalization of 
Discussion
Our study shows that high myofilament Ca 2+ sensitivity in human HCM myocardium is independent of the presence of a sarcomere mutation and at least partly explained by protein hypophosphorylation. Sarcomere mutations may modify Ca 2+ sensitivity, but the direction and magnitude of the change depend on the affected gene. Impaired length-dependent activation of sarcomeres represents a common pathomechanism underlying HCM and could not be corrected by PKA treatment in HCM with missense mutations in genes encoding thick-and thin-filament proteins. Moreover, our troponin exchange experiments provide direct proof that mutant troponin impairs lengthdependent activation. Our data indicate that mutant proteins resulting from missense mutations could perturb lengthdependent sarcomere activation and underlie cardiac dysfunction observed at early stages of HCM disease development.
Myofilament Ca 2+ Sensitivity and Phosphorylation Background
Our studies in human HCM with mutations in both thick-and thin-filament proteins showed high myofilament Ca 2+ sensitivity at a sarcomere length of 2.2 μm ( Figure 1A ). This is in agreement with previous studies in transgenic mouse models and in vitro studies with mutant proteins, which indicate that HCM sarcomere mutations sensitize myofilaments to calcium. 3, 12, 13, 25 However, the higher Ca 2+ sensitivity in sarcomere mutationpositive HCM groups compared with nonfailing donors coincided with lower phosphorylation levels of cMyBP-C and cTnI ( Figure 3A) . The difference in myofilament Ca 2+ sensitivity between sarcomere mutation-positive HCM and nonfailing donor can thus be partly explained by hypophosphorylation of sarcomeric proteins rather than the sarcomere gene mutation itself.
A possible explanation for the low phosphorylation levels may reside in a blunted β-adrenergic response in patients with HCM. A blunted response to isoproterenol, a β-adrenoreceptor agonist, has been reported in transgenic mice harboring TPM1 and MYH7 mutations. 26, 27 Moreover, reduced β-adrenoreceptor density has been reported in patients with HCM. 28 Treatment of HCM samples with PKA increased phosphorylation of the PKA target proteins (Figures 3 and  4 and Online Figure II) and normalized myofilament Ca 2+ sensitivity in MYBPC3 mut , TPM1 mut , and HCM smn to values observed in nonfailing donors. In contrast, after PKA, higher myofilament Ca 2+ sensitivity was still present in MYH7 mut and TNNT2 mut , suggesting a Ca 2+ -sensitizing effect by these mutations. Interestingly, PKA treatment significantly lowered Ca 2+ sensitivity of the TNNI3 mut R145W compared with donor. This observation contrasts with transgenic animal models and reconstituted thin filaments using recombinant human mutant cTnI. [29] [30] [31] It has been suggested that the Ca 2+ -sensitizing action of mutations in the inhibitory region of cTnI (residues 137-148) directly impairs the intrinsic inhibitory activity of cTnI. 29, 30 A possible explanation for the contradicting results compared with our TNNI3 mut samples may reside in the amount of endogenous mutant protein expression. Using adenovirus gene transfection to incorporate the cTnI R145W mutant into adult rat cardiomyocytes, Davis et al 32 observed no elevation of myofilament Ca 2+ sensitivity, which was attributed to poor incorporation (≈35%) of mutant protein into the sarcomeric structure compared with wild-type cTnI. In addition, the phosphorylation background of the sarcomeres may have been different among studies.
Overall, our data show that high Ca 2+ sensitivity is not a specific characteristic of human sarcomere mutationpositive HCM because a similarly high myofilament Ca 2+ sensitivity was found in HCM smn compared with donors, which may be ascribed to reduced β-adrenergic signaling as part of cardiomyopathy development. Although PKA is the archetypical kinase involved in modulating Ca 2+ sensitivity through cTnI and cMyBP-C phosphorylation, it is by no means the only kinase that phosphorylates myofilament proteins. Both cTnI and cMyBP-C are targets for a whole range of kinases. [33] [34] [35] [36] [37] cMyBP-C phosphorylation is thought to by LIZA GORSTAN on September 4, 2013 http://circres.ahajournals.org/ Downloaded from mainly affect cross-bridge cycling kinetics, 38 although a role in mediating Ca 2+ sensitivity of force has been suggested. 39 cTnI is considered to be the key regulator of Ca 2+ sensitivity, and it is mainly through phosphorylation of Ser23 and Ser24 that PKA exerts its Ca 2+ desensitizing effect, although many other phosphorylation sites have been identified. 40 Phosphorylation is but one of many possible posttranslational modifications. Recent reports have hinted at the possible involvement of other posttranslational modifications in the regulation of sarcomere function such as oxidation and S-glutathionylation 41 or O-GlcNAcylation. 42 It would thus be an oversimplification to propose that a reduction in PKA phosphorylation of sarcomere proteins is solely responsible for the myofilament changes in HCM. However, the baseline Ca 2+ sensitivity seems to be dominated by the relatively low phosphorylation levels of PKA myofilament target proteins compared with donors. Higher phosphorylation levels mimicked by exogenous PKA treatment, as would be induced during increased cardiac stress (eg, exercise), unveils a higher, similar, or even lower myofilament Ca 2+ sensitivity in HCM, depending on the affected gene. Our findings suggest diverse mutation-induced changes in Ca 2+ sensitivity, whereas high myofilament Ca 2+ sensitivity is partly explained by secondary disease-related changes in protein phosphorylation.
Impairment of Length-Dependent Sarcomere Activation in HCM
Our data indicate that mutant sarcomeric proteins in HCM perturb length-dependent activation of myofilaments, which may contribute to early cardiac dysfunction observed in sarcomere mutation carriers. Studies in transgenic mouse models and troponin-exchange techniques with mouse tissue harboring HCM mutations were not conclusive because a reduced or normal length-dependent activation was found compared with controls. 27, [43] [44] [45] [46] The recent study of Ford et al 46 may shed some light on these previous observations. Those authors studied length-dependent differences in mice expressing TNNT2 mutations either in an α-MyHC (predominant in murines) or in a β-MyHC (predominant in healthy adult human hearts) background. It was observed that mice expressing the R92L mutation in the physiological α-MyHC background presented a normal length-dependent Ca 2+ activation, whereas in the presence of the slow-cycling β-MyHC isoform, length dependence was lost. 46 Defects in length-dependent sarcomere properties were not similar in all HCM samples because the blunted length-dependent increase in myofilament Ca 2+ sensitivity was corrected to donor values by exogenous PKA in truncating MYBPC3 mut and HCM smn , whereas it remained defective in HCM with missense mutations in MYBPC3, MYH7, TNNT2, TNNI3, and TPM1. Moreover, the increase in maximal force 4) . Right, A suspension of cardiomyocytes from a TNNI3 mut heart exchanged with 1 mg/mL wild-type human recombinant troponin complex. Similar amounts were loaded on the blots (shown by Ponceau-stained actin) to allow cTnT analysis within the linear detection range. B, The length-dependent activation was significantly lower compared with donor in all TNNT2 mut cells harboring varying amounts of mutant cTnT (100% without exchange and 38%, 22%, and 14% in cells exchanged with increasing concentrations of unphosphorylated recombinant wild-type troponin). C, Measurements were also performed in exchanged cardiomyocytes, which were subsequently treated with protein kinase A (PKA) to normalize cTnI phosphorylation. Pretreatment with exogenous PKA was not able to recover the blunted length-dependent activation in TNNT2 mut cells with 38% of mutant cTnT, but it did recover the reduced length dependence of TNNT2 mut exchanged with 78% and 86% wild-type troponin. D, The length-dependent activation was significantly lower in TNNI3 mut cells exchanged with ≈90% unphosphorylated recombinant wild-type troponin (wt-cTn) compared with donor cells. E, Pretreatment with exogenous PKA restored the blunted length-dependent activation in TNNI3 mut cells exchanged with wt-cTn complex to donor values. *P<0.05 vs donor; §P<0.05 vs TNNT2 mut or TNNI3 mut .
by LIZA GORSTAN on September 4, 2013 http://circres.ahajournals.org/ Downloaded from generating capacity on an increase in sarcomere length was almost entirely absent in HCM with troponin mutations (Table  2) . Although PKA increased phosphorylation of cTnI and cMyBP-C and reduced myofilament Ca 2+ sensitivity at 2.2 μm in all HCM samples (except in the homozygous TNNT2 mut ), it did not restore length-dependent activation in HCM samples with missense mutations. Intriguingly, a negative myofilament length-dependent activation was observed after PKA in the TPM1 mut sample (Figure 2D ), suggesting that length-dependent activation is even more impaired during increased cardiac stress.
The blunted length-dependent activation may be partly related to the relatively low phosphorylation of PKA targets and high baseline myofilament Ca 2+ sensitivity. The suggestion that PKA-mediated myofilament protein phosphorylation has a modulatory role in length-dependent activation comes from studies in ferret papillary muscles 23 in which isoprenaline, a stimulator of the β-adrenergic receptor pathway, enhanced the length-dependent change in the force-Ca 2+ relation. Studies in cardiac tissue in which cTnI was replaced by skeletal TnI, which lacks the PKA target serines (Ser23/24), showed higher myofilament Ca 2+ sensitivity but a significantly reduced length-dependent activation, 24, 47 indicating a role for cTnI phosphorylation in length-dependent activation. A study by Cazorla et al 44 in transgenic mice lacking cMyBP-C demonstrated lower length-dependent activation than wild-type mice that could not be restored by exogenous PKA treatment, which suggests that cMyBP-C is needed for proper length-dependent sarcomere activation. In our human samples with truncating MYBPC3 mutations, impaired length-dependent activation was corrected to donor values by PKA. Our previous study in HCM with truncating mutations in MYBPC3 showed reduced expression of full-length cMyBP-C to ≈70% compared with donor values (ie, haploinsufficiency). Overall, our studies in human HCM with MYBPC3 truncation mutations indicate that the presence of ≈70% of full-length cMyBP-C protein in the sarcomere is sufficient to preserve the length-dependent properties of the sarcomeres. 15 The perturbations in length-dependent activation in HCM with mutations in thin-filament genes may be explained by the 3-state model of filament transition in which the troponin-tropomyosin complex has a central regulatory role. Myofilament contraction and force production are tightly regulated by the troponin-tropomyosin complex, which regulates the interaction between the actin and myosin filaments. It is believed that the myofilaments exist in a dynamic equilibrium between 3 biochemical transitions ( Figure 6 ) that reflect different interactions between actin and myosin, called the blocked (B-state), closed (C-state), and open (M-state) states of thin-filament regulation. 48, 49 In the B-state, Ca 2+ is not bound to cardiac troponin C, and tropomyosin sterically blocks myosin-binding sites on F-actin ( Figure 6A ). In the C-state, Ca 2+ binds to cardiac troponin C, which changes conformation of the troponin-tropomyosin complex, resulting in non-tension-generating cross-bridges, which bind weakly to F-actin (ie, weakly bound cross-bridges; Figure 6B ). [49] [50] [51] The M-state involves strong binding of tension-generating cross-bridges, which results in myofilament contraction and force development ( Figure 6C ). [49] [50] [51] Because of the central roles of cTnT and cTnI in the transition from the B-state to the C-state, [52] [53] [54] it is likely that mutation-induced irregularities in protein interactions may translate into thin-filament abnormalities.
The C-terminal half of cTnI docks the troponin-tropomyosin complex onto the outer domain of F-actin at low cytoplasmic [Ca 2+ ], 58 stabilizing the formation of the B-state. Interestingly, ≈86% of cTnI HCM-causing mutations (dashed red circle in Figure 6D ), including the one present in our study, are found in the C-terminal half of cTnI (residues 137-210), a region responsible for actin binding. 25, 60 Indeed, disruption of the B-state has been suggested in HCM-causing mutations affecting not only cTnI 61 but also cTnT. 62, 63 The relevance of the transition from the B-to the C-state for proper lengthdependent activation has been shown by Smith and Fuchs, 64 who were the first to provide evidence for a length-sensitive step in the transitions of thin-filament activation. A reduction in ionic strength (<0.05 mol/L), known to shift the B-state equilibrium toward a stable C-state, 65 coincided with impairment of length-dependent activation. 64 The blunted lengthdependent increase in myofilament Ca 2+ sensitivity observed in the thin-filament mutation groups can thus be explained by disruption of the B-state and an increased number of weakly bound cross-bridges in the C-state.
Eleven HCM mutations have been identified in αtropomyosin. 60 To the best of our knowledge, the present study is the first to analyze the effects of an HCM-causing mutation (M281T) in the overlap region of tropomyosin, which has a central role in cooperative activation of the thin filament. 66, 67 The steepness of the force-Ca 2+ relation, which is an indicator of the relative number of near-neighbor interacting sites, was significantly lower in TPM1 mut compared with donors (1.98±0.37 and 3.33±0.11, respectively; Figure 2B ), indicative of impairment of the cooperative response in activating the thin filament. Palm et al 68 demonstrated that tropomyosin overlap regions are required for proper formation of a ternary complex with the N-terminal tail of cTnT. Because the N-terminal region of cTnT is needed to maintain the thin filament in the B-state, 53, 54 it is likely that mutations in the overlap region of α-tropomyosin structurally impair formation of the B-state and thereby impair length-dependent activation of myofilaments.
Previous studies indicated that myosin is not involved in the formation of the first 2 equilibrium states, that is, B-and C-states. [49] [50] [51] However, myosin is crucial for formation of the M-state (myosin-induced) because strong binding of tensiongenerating cross-bridges is required for thin-filament activation and force production. [49] [50] [51] Because 5 of the 6 samples used in our study have mutations in the myosin S1 domain, responsible for actin binding, 69 it is likely that the deleterious effects of MYH7 mutations occur via perturbation of the M-state. A recent study by Farman et al 70 highlights the essential role of the orientation of the myosin heads that precede thin-filament activation for proper lattice spacing and length-dependent activation. Thus, altered myosin head orientation, as a result of mutations, may impair formation of the M-state and affect length-dependent activation.
The possible involvement of cMyBP-C in the modulation of thin-filament activity has only recently been addressed.
Electron microscopy and 3-dimensional reconstruction of thin filaments with cMyBP-C suggest that the N-terminal extension of cMyBP-C could modulate the movement of tropomyosin on F-actin and interfere with actomyosin interactions, possibly involved in the regulation of thin-filament activation. 71 The MYBPC3 missense mutations in our study are located along the N-terminal extension of cMyBP-C and may alter the tropomyosin-actin interaction and thereby impair length-dependent activation.
Study Limitations and Clinical Implications
Although we were able to study a large collection of human HCM samples with different mutations in thick-and thinfilament proteins, care must be taken when extrapolating our Figure 6 . Schematic drawing of the thin-filament functional unit. Seven actin monomers (gray) spanned by 1 tropomyosin dimmer (red) and 1 troponin complex: cardiac troponin C (cTnC; pink), cardiac troponin I (cTnI; blue), and cardiac troponin T (cTnT; orange). N and C indicate the N-and C-terminal protein ends, respectively. Dark-blue tropomyosin depicts near-neighbor tropomyosin dimmer interaction. 55, 56 The orientation of thin-filament proteins is as follows: The N-terminal region of cTnT points toward the pointed end (M-band), whereas the core domain of the troponin complex is oriented to the barbed end (Z-disk). 57 Interacting sites and structural location of actin-tropomyosin-troponin proteins are matched in accordance with available literature. 25, 50, 51, 56, 58, 59 Cardiac TnI residues 1 to 34 are arbitrarily positioned. Our drawing follows the proposed mechanism for Ca 2+ regulation of contraction proposed by Murakami et al. 58 A, B-state (blocked); when ATP is present and cytoplasmic [Ca 2+ ] is low such that Ca 2+ is not bound to cTnC, tropomyosin sterically blocks the myosin-binding sites on F-actin. B, C-state (Ca 2+ -induced); cytoplasmic [Ca 2+ ] rises such that Ca 2+ binds to cTnC, inducing conformational changes of the troponin complex, resulting in an ≈25º movement of tropomyosin on the thin filament, thereby exposing most of the myosin-binding sites on F-actin. Note the movement of tropomyosin away from subdomains 1 and 2 of F-actin. In the C-state, the myofilament is not yet activated because non-tension-generating cross-bridges bind weakly to F-actin. C, M-state (myosininduced); involves the strong binding of tension-generating cross-bridges that induce an additional ≈10º movement of tropomyosin on F-actin, resulting in myofilament activation and contraction. Note the transition of tropomyosin into subdomains 3 and 4 of F-actin. D, Solid arrows depict the location of mutation sites on thin-filament proteins present in our human hypertrophic cardiomyopathy samples. cTnT residues 1 to 65 are shortened to fit the enlarged scale.
by LIZA GORSTAN on September 4, 2013 http://circres.ahajournals.org/ Downloaded from findings to all patients with HCM. Our HCM population consisted of patients with left ventricular outflow tract obstruction, and the patient with the homozygous TNNT2 mutation had end-stage heart failure. Our data highlight that mutationinduced changes in myofilament Ca 2+ sensitivity and lengthdependent sarcomere activation are diverse and depend on the affected gene, and most likely location and type of the mutation in the affected protein. We provide evidence that mutant protein may impair sarcomere function at ≈38% expression ( Figure 5C ), which emphasizes the importance of studying the mutant protein level at which cardiac performance is impaired. Future studies in transgenic mice models and human myectomy samples are warranted to extend our findings to a broader set of sarcomere mutations and to assess the toxic dose of mutant proteins.
Although sarcomere mutation-negative patients are commonly used as control group, we cannot completely rule out the presence of rare mutations. However, because our cardiomyocyte analyses revealed no functional impairments (PKAnormalized length-dependent activation in HCM smn ), the likelihood of the presence of a rare mutation is low.
Our study revealed perturbed sarcomere length-dependent activation as a common mechanism underlying cardiac dysfunction in HCM. Pathological hypertrophy presumably reflects the compensatory response of the heart to counteract impaired sarcomere defects such as the blunted length-dependent myofilament activation. The relatively low force-generating capacity of cardiomyocytes and the inability to increase force on an increase in sarcomere length may in part underlie cardiac dysfunction and initiate compensatory hypertrophy. Pak et al 72 showed a blunted end-systolic pressure-volume relation in patients with HCM, suggesting that the hearts were unable to properly recruit preload to augment contractility. The latter observation may be explained by cardiac remodeling. However, likewise, the mutation-induced blunted length-dependent sarcomere activation may limit preload-mediated contractile reserve of the heart in patients with HCM. Our study, in combination with others, 6-10 supports the hypothesis that defective sarcomere function as a result of gene mutations is central to early stages of HCM disease and precedes development of hypertrophy. Moreover, the blunted increase in myofilament Ca 2+ sensitivity on an increase in length may alter Ca 2+ buffering in the cardiomyocytes and provide a substrate for arrhythmias.
